Wrong end of the hormone

Search for KPV alongside “libido” or “HSDD” and you will find it: vendor copy that lists sexual desire among the tripeptide’s benefits, stack guides that pair it with PT-141 as if they were two strengths of the same thing, forum threads asking whether KPV is “the gentler PT-141.” None of it is malicious. It is a chain of reasonable-sounding steps that arrives somewhere false, and it is worth walking the chain rather than just declaring the conclusion wrong.

Step one: hypoactive sexual desire disorder – persistent, distressing loss of sexual desire not explained by another condition, a relationship, or a drug – has exactly one approved on-demand treatment, and it is a peptide. Bremelanotide, sold as Vyleesi, was approved in June 2019 for premenopausal women with acquired, generalised HSDD. Step two: bremelanotide is a melanocortin, an analog of the pigment hormone α-MSH. Step three: KPV is also a melanocortin, also derived from α-MSH, and its own catalog page will tell you so. Step four, unstated: molecules in the same family, from the same parent, do the same sort of thing.

Steps one to three are true. Step four is where it breaks, and it breaks for a reason that is written into the two molecules’ sequences. They were not cut from the same part of the hormone. They were cut from opposite ends, and the end that KPV comes from was chosen because it does not do what bremelanotide does.

α-MSH is thirteen amino acids long, and pharmacologists have known since the 1980s that it carries at least two separable messages. The first sits in the middle: residues six to nine, His-Phe-Arg-Trp, are the melanocortin pharmacophore, the four-residue motif that every one of the five melanocortin receptors recognises. Swap or delete those four and the peptide stops binding MC1R, stops binding MC4R, stops doing anything a receptor would notice. Everything the family is famous for – the pigment, the appetite suppression, the adrenal signal, the sexual effects – runs through that tetrapeptide docking into one receptor or another.

The second message sits at the far end. Residues eleven to thirteen, Lys-Pro-Val, were identified in 1989 as the smallest fragment that still reproduced the parent hormone’s anti-inflammatory effect – a fever-lowering, cytokine-quieting action that, awkwardly for the textbook, did not seem to need a melanocortin receptor at all. That fragment is KPV. It contains none of the pharmacophore. It cannot dock a melanocortin receptor because it does not carry the part of the molecule that does the docking. In binding and signalling assays it does not activate MC4R at any concentration a pharmacologist would take seriously; the residual argument in the literature is over whether it has a faint interaction with MC1R, the pigment receptor, not whether it touches the receptor that governs desire.

This is not a subtle distinction the vendors missed. It is the whole point of the molecule. KPV exists as a research compound precisely because someone wanted the anti-inflammatory clause of α-MSH without the receptor message – without the tanning, without the appetite effect, and without the sexual side-effects that the receptor message produces. Selling KPV for desire is selling it for the property it was engineered to lack.

To see why the pharmacophore matters so much, follow the other fragment’s history, because the HSDD drug was an accident. In the late 1980s Victor Hruby and Mac Hadley at the University of Arizona were trying to build a longer-lasting α-MSH for a sensible purpose: a tan without the sun, for people at risk of skin cancer. They kept the His-Phe-Arg-Trp core, swapped one residue for its mirror image to resist enzymes, and locked the middle of the peptide into a ring so it would hold its shape. The result, melanotan II, is essentially the pharmacophore and its scaffolding with everything else trimmed away – seven residues instead of thirteen, and the tail with KPV in it is gone entirely.

In the first human tanning studies in the mid-1990s the men given melanotan II tanned, and several of them also reported spontaneous erections, hours of them, along with yawning and nausea. A follow-up crossover study in men with psychogenic erectile dysfunction confirmed that the effect was real and placebo-resistant. The peptide was reaching MC4 receptors in the hypothalamus, and MC4R, it turned out, sits on a circuit that gates sexual arousal in both sexes – in rats, agonists at that receptor produce erections in males and solicitation behaviour in females, and the effect vanishes in animals with the receptor knocked out.

Having established that KPV is the wrong molecule, honesty requires saying how well the right one works, because the size of bremelanotide’s reputation on the catalog page is part of why the rumour spread to its neighbours. The approval rests on two identical phase-3 trials, RECONNECT, which together randomised about 1,250 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo, self-injected on demand at least 45 minutes before anticipated sex, for 24 weeks.

Both co-primary endpoints were met, and both are small. On the desire domain of the Female Sexual Function Index, which runs from 1.2 to 6, the drug arm improved by roughly a third of a point more than placebo. On the distress item – how bothered you are by your low desire, scored 0 to 4 – the gap was about the same. The trials’ key secondary endpoint, the one the earlier HSDD drug flibanserin had been judged on, was the number of satisfying sexual events per month. Bremelanotide did not separate from placebo on it. The FDA had, before the trial, agreed that events were a poor measure for an on-demand drug – a woman decides when to inject – and accepted the desire and distress scores instead. That is a defensible regulatory position. It is also why the label describes a modest change in how women felt rather than a change in what happened.

The other side of the ledger is not modest. Four in ten women on bremelanotide had nausea, against about one in a hundred on placebo, and roughly one in eight needed an anti-emetic. One in five flushed. Blood pressure rose by around six points systolic for a few hours after each dose, which is why the label caps use at one dose a day and eight a month and contraindicates the drug in uncontrolled hypertension. And in about one per cent of participants the pigment receptor did what the pigment receptor does: focal darkening of the face, gums, or breasts, more likely in darker skin and with more than eight doses a month, and not always reversible. The tanning peptide never entirely left the molecule.

Against that there is, for KPV, nothing to weigh. Not a negative result – nothing. No published study in any species has tested KPV on sexual behaviour, erection, arousal, or desire. There is no clinical trial of KPV in humans for any indication, sexual or otherwise; its evidence base is cells and rodents, almost entirely in inflammation models, with colitis the best developed. The receptor pharmacology predicts that such a study, if run, would find nothing, because the molecule lacks the motif that engages the receptor the effect depends on. But the claim on the vendor page is not resting on a prediction. It is resting on a name.

One more mechanism of confusion deserves naming, because this site is guilty of the raw material. Family-level descriptions of the melanocortins – ours included – list “pigmentation, appetite, inflammation, and sexual function” in a single breath. That is an accurate description of what the receptor family does. It is not a description of any one ligand, and the entire interest of the family is that its members split those jobs apart: setmelanotide takes appetite, afamelanotide takes pigment, bremelanotide takes desire and drags pigment along, KPV takes inflammation and nothing else. Reading a family property as a molecule property is the same mistake as assuming every steroid builds muscle.

Settled: the sexual effects of the melanocortin system run through MC4R and require the His-Phe-Arg-Trp pharmacophore; KPV does not contain it and does not activate MC4R; no study has examined KPV and sexual function; bremelanotide is the melanocortin with an HSDD indication, and its measured benefit is a small shift on desire and distress scores with no demonstrated change in satisfying sexual events and a heavy nausea burden.

Open: whether KPV’s faint reported interaction with MC1R is real or an artefact, which matters for its anti-inflammatory mechanism and for nothing else; whether bremelanotide’s desire effect would hold in postmenopausal women or men, where it has not been approved; whether an MC4R agonist can ever be built that leaves the pigment receptor alone. None of those open questions puts KPV anywhere near a bedroom. If the catalog page says otherwise, it has the hormone by the wrong end.